Compare · CI vs TLSI
CI vs TLSI
Side-by-side comparison of The Cigna Group (CI) and TriSalus Life Sciences Inc. (TLSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and TLSI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $78.04B, about 380.4x TLSI ($205.1M).
- Over the past year, CI is down 5.5% and TLSI is down 35.4% - CI leads by 29.9 points.
- TLSI has been more active in the news (8 items in the past 4 weeks vs 4 for CI).
- CI has more recent analyst coverage (25 ratings vs 6 for TLSI).
- Company
- The Cigna Group
- TriSalus Life Sciences Inc.
- Price
- $296.44+0.49%
- $3.58+7.19%
- Market cap
- $78.04B
- $205.1M
- 1M return
- +2.59%
- -21.32%
- 1Y return
- -5.49%
- -35.38%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 8
- Recent ratings
- 25
- 6
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group
Latest TLSI
- TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
- Amendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.
- Chief Commercial Officer Marshak Richard sold $1,450 worth of shares (543 units at $2.67), decreasing direct ownership by 0.43% to 125,101 units (SEC Form 4) to cover withholding tax
- Director Wahlstrom Mats bought $151,800 worth of shares (60,000 units at $2.53), increasing direct ownership by 69% to 147,555 units (SEC Form 4)
- Director Stansky Michael P bought $1,525,000 worth of shares (610,000 units at $2.50), increasing direct ownership by 49% to 1,240,722 units (SEC Form 4)
- Chief Financial Officer Patience David bought $17,253 worth of shares (7,100 units at $2.43), increasing direct ownership by 3% to 275,757 units (SEC Form 4)
- CEO and President Szela Mary T bought $102,776 worth of shares (39,682 units at $2.59), increasing direct ownership by 4% to 1,065,215 units (SEC Form 4) to cover withholding tax
- Director Gordon Gary B. bought $24,600 worth of shares (10,000 units at $2.46), increasing direct ownership by 16% to 72,510 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by TriSalus Life Sciences Inc.
- Director Gordon Gary B. was granted 52,754 shares, increasing direct ownership by 541% to 62,510 units (SEC Form 4)